Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (Javelin DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02951156
Recruitment Status : Active, not recruiting
First Posted : November 1, 2016
Last Update Posted : January 29, 2019
Sponsor:
Collaborator:
EMD Serono
Information provided by (Responsible Party):
Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : March 20, 2020
  Estimated Study Completion Date : May 29, 2021